PT-141
Bremelanotide — Sexual Health and Desire
Molecular Data
- Formula
- C50H68N14O10
- Molecular Weight
- 1025.18 g/mol
01
Overview
PT-141 (Bremelanotide) is a synthetic melanocortin analogue derived from the cyclic alpha-MSH peptide Melanotan II. It is the only FDA-approved peptide (as Vyleesi®) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally via the CNS to drive sexual desire and arousal.
02
Mechanism of Action
PT-141 activates melanocortin receptors MC1R, MC3R, and MC4R in the hypothalamus and limbic system, directly stimulating sexual desire circuits. The MC4R pathway in the paraventricular nucleus is primarily responsible for its pro-sexual effects. This central mechanism is distinct from vascular mechanisms of PDE5 inhibitors.
03
Research Highlights
FDA approval in 2019 as Vyleesi® for HSDD in premenopausal women
Phase II/III trials demonstrate significant improvement in satisfying sexual events
Melanocortin receptor mapping studies define MC4R as the primary mediator of pro-sexual effects
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, typically 30–45 minutes before intended effect. Research protocols use as-needed dosing.
Dosage Guidelines
Cycle Length
As-needed dosing; cap at 2 doses per 24 hours and 8 doses per month in research.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 10 mg vial
Concentration
5 mg/mL
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
PT-141 (Bremelanotide) acts on melanocortin receptors (not PDE5). Nausea is common at higher doses; start low.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
PT-141 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
PT-141 Knowledge Graph
Explore how PT-141 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
PT-141 — Common Research Questions
What is PT-141?
PT-141 (Bremelanotide) is a synthetic melanocortin analogue derived from the cyclic alpha-MSH peptide Melanotan II. It is the only FDA-approved peptide (as Vyleesi®) for the treatment of hypoactive se... PT-141 belongs to the Other research category and is studied for its bremelanotide — sexual health and desire.
How does PT-141 work?
PT-141 activates melanocortin receptors MC1R, MC3R, and MC4R in the hypothalamus and limbic system, directly stimulating sexual desire circuits. The MC4R pathway in the paraventricular nucleus is primarily responsible for its pro-sexual effects. This central mechanism is distinct from vascular mechanisms of PDE5 inhibitors.
What are the key research benefits of PT-141?
Central nervous system activation of sexual desire. FDA-approved for female HSDD. Effective in both men and women in research. Non-hormonal mechanism — no alteration of sex hormone levels. Erectile function support in males. Lubrication and arousal enhancement in research.
What is the molecular structure of PT-141?
PT-141 has the molecular formula C50H68N14O10 and a molecular weight of 1025.18 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about PT-141?
FDA approval in 2019 as Vyleesi® for HSDD in premenopausal women Phase II/III trials demonstrate significant improvement in satisfying sexual events Melanocortin receptor mapping studies define MC4R as the primary mediator of pro-sexual effects These findings are based on preclinical and clinical research. PT-141 is a research compound and these studies do not constitute medical advice.
Is PT-141 FDA approved?
Yes. PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
What category does PT-141 belong to?
PT-141 belongs to the Other category, which focuses on a collection of specialized peptides studied across various physiological domains including reproductive health, pigmentation, and growth factor signaling. You can explore more compounds in this category on the Other pillar page.
Related Articles
PT-141: Central Nervous System Activation of Sexual Desire
Understanding how PT-141 differs from PDE5 inhibitors and its Phase III HSDD clinical trial data.
DSIP: Delta Sleep-Inducing Peptide
The discovery, mechanism, and stress-modulation research behind DSIP's sleep-promoting effects.
Kisspeptin: The Gatekeeper of the HPG Axis
How Kisspeptin's pulsatile signaling controls GnRH release and its implications for reproductive research.
Scientific References
Kingsberg et al. — Phase III trials for HSDD (Obstet Gynecol, 2019)
FDA approval as Vyleesi® (bremelanotide), 2019
FDA approval in 2019 as Vyleesi® for HSDD in premenopausal women
Phase II/III trials demonstrate significant improvement in satisfying sexual events
Melanocortin receptor mapping studies define MC4R as the primary mediator of pro-sexual effects